352 related articles for article (PubMed ID: 24554781)
21. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents.
Bagatell R; Paine-Murrieta GD; Taylor CW; Pulcini EJ; Akinaga S; Benjamin IJ; Whitesell L
Clin Cancer Res; 2000 Aug; 6(8):3312-8. PubMed ID: 10955818
[TBL] [Abstract][Full Text] [Related]
22. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor.
Li T; Chen X; Dai XY; Wei B; Weng QJ; Chen X; Ouyang DF; Yan R; Huang ZJ; Jiang HL; Zhu H; Lu JJ
Toxicol Appl Pharmacol; 2017 Sep; 330():65-73. PubMed ID: 28711525
[TBL] [Abstract][Full Text] [Related]
23. Ganetespib and HSP90: translating preclinical hypotheses into clinical promise.
Proia DA; Bates RC
Cancer Res; 2014 Mar; 74(5):1294-300. PubMed ID: 24556722
[TBL] [Abstract][Full Text] [Related]
24. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
25. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
26. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells.
Massey AJ; Williamson DS; Browne H; Murray JB; Dokurno P; Shaw T; Macias AT; Daniels Z; Geoffroy S; Dopson M; Lavan P; Matassova N; Francis GL; Graham CJ; Parsons R; Wang Y; Padfield A; Comer M; Drysdale MJ; Wood M
Cancer Chemother Pharmacol; 2010 Aug; 66(3):535-45. PubMed ID: 20012863
[TBL] [Abstract][Full Text] [Related]
27. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Chang KY; Tsai SY; Wu CM; Yen CJ; Chuang BF; Chang JY
Clin Cancer Res; 2011 Nov; 17(22):7116-26. PubMed ID: 21976531
[TBL] [Abstract][Full Text] [Related]
28. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
29. PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells.
Kolev VN; Wright QG; Vidal CM; Ring JE; Shapiro IM; Ricono J; Weaver DT; Padval MV; Pachter JA; Xu Q
Cancer Res; 2015 Jan; 75(2):446-55. PubMed ID: 25432176
[TBL] [Abstract][Full Text] [Related]
30. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
32. Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer.
Liu H; Lu J; Hua Y; Zhang P; Liang Z; Ruan L; Lian C; Shi H; Chen K; Tu Z
Cell Death Dis; 2015 Jan; 6(1):e1595. PubMed ID: 25590805
[TBL] [Abstract][Full Text] [Related]
33. A novel C-terminal heat shock protein 90 inhibitor that overcomes STAT3-Wnt-β-catenin signaling-mediated drug resistance and adverse effects.
Lee HJ; Min HY; Yong YS; Ann J; Nguyen CT; La MT; Hyun SY; Le HT; Kim H; Kwon H; Nam G; Park HJ; Lee J; Lee HY
Theranostics; 2022; 12(1):105-125. PubMed ID: 34987637
[No Abstract] [Full Text] [Related]
34. Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma.
Bekki H; Kohashi K; Maekawa A; Yamada Y; Yamamoto H; Harimaya K; Hakozaki M; Nabeshima K; Iwamoto Y; Oda Y
BMC Cancer; 2015 Oct; 15():804. PubMed ID: 26502919
[TBL] [Abstract][Full Text] [Related]
35. The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer.
He S; Smith DL; Sequeira M; Sang J; Bates RC; Proia DA
Invest New Drugs; 2014 Aug; 32(4):577-86. PubMed ID: 24682747
[TBL] [Abstract][Full Text] [Related]
36. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
37. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models.
Proia DA; Sang J; He S; Smith DL; Sequeira M; Zhang C; Liu Y; Ye S; Zhou D; Blackman RK; Foley KP; Koya K; Wada Y
Invest New Drugs; 2012 Dec; 30(6):2201-9. PubMed ID: 22227828
[TBL] [Abstract][Full Text] [Related]
38. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy.
Bao R; Lai CJ; Qu H; Wang D; Yin L; Zifcak B; Atoyan R; Wang J; Samson M; Forrester J; DellaRocca S; Xu GX; Tao X; Zhai HX; Cai X; Qian C
Clin Cancer Res; 2009 Jun; 15(12):4046-57. PubMed ID: 19509149
[TBL] [Abstract][Full Text] [Related]
39. Characterizing the role of Hsp90 in production of heat shock proteins in motor neurons reveals a suppressive effect of wild-type Hsf1.
Taylor DM; Tradewell ML; Minotti S; Durham HD
Cell Stress Chaperones; 2007; 12(2):151-62. PubMed ID: 17688194
[TBL] [Abstract][Full Text] [Related]
40. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]